Advances in Immunotherapy of Malignant Pleural Mesothelioma

被引：9
作者：
Liao, Dongying [1 ,2 ]
Yu, Yongchao [1 ,2 ]
Mei, Qingyun [1 ,2 ]
Wang, Ziwei [1 ,2 ]
Li, Xiaojiang [1 ,2 ]
Jia, Yingjie [1 ,2 ]
Kong, Fanming [1 ,2 ]
机构：
[1] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Oncol, Anshanxi Rd, Tianjin 300193, Peoples R China
[2] Nat Clin Res Ctr Chinese Med Acupuncture & Moxib, Tianjin 300193, Peoples R China
来源：
ONCOTARGETS AND THERAPY | 2021年 / 14卷
基金：
中国国家自然科学基金;
关键词：
malignant pleural mesothelioma; immunotherapy; progression; ipilimumab; nivolumab; PHASE-II TRIAL; PLUS CISPLATIN; CHECKMATE; 743; OPEN-LABEL; MULTICENTER; NIVOLUMAB; CHEMOTHERAPY; BEVACIZUMAB; GEMCITABINE; CARBOPLATIN;
D O I：
10.2147/OTT.S317434
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to treat the unresectable MPM in treatment-naive patients as a first-line therapy by the FDA in October 2020. Immunotherapy is expected to be the best choice for MPM treatment. In the following article, the past treatment plan and the progress of immunotherapy for MPM will be reviewed.
引用
收藏
页码：4477 / 4484
页数：8
相关论文
共 46 条
[1]   Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review [J].
Abdel-Rahman, Omar ;
Kelany, Mohamed .
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (05) :533-549
[2]   A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma [J].
Arrieta, Oscar ;
Lopez-Macias, Diego ;
Mendoza-Garcia, Victor-Osvaldo ;
Bacon-Fonseca, Ludwing ;
Munoz-Montano, Wendy ;
Macedo-Perez, Eleazar-Omar ;
Muniz-Hernandez, Sae ;
Blake-Cerda, Monika ;
Corona-Cruz, Jose-Francisco .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) :975-982
[3]   First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial [J].
Baas, Paul ;
Scherpereel, Arnaud ;
Nowak, Anna K. ;
Fujimoto, Nobukazu ;
Peters, Solange ;
Tsao, Anne S. ;
Mansfield, Aaron S. ;
Popat, Sanjay ;
Jahan, Thierry ;
Antonia, Scott ;
Oulkhouir, Youssef ;
Bautista, Yolanda ;
Cornelissen, Robin ;
Greillier, Laurent ;
Grossi, Francesco ;
Kowalski, Dariusz ;
Rodriguez-Cid, Jeronimo ;
Aanur, Praveen ;
Oukessou, Abderrahim ;
Baudelet, Christine ;
Zalcman, Gerard .
LANCET, 2021, 397 (10272) :375-386
[4]   Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales [J].
Beckett, P. ;
Edwards, J. ;
Fennell, D. ;
Hubbard, R. ;
Woolhouse, I. ;
Peake, M. D. .
LUNG CANCER, 2015, 88 (03) :344-348
[5]   Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes [J].
Betti, Marta ;
Aspesi, Anna ;
Ferrante, Daniela ;
Sculco, Marika ;
Righi, Luisella ;
Mirabelli, Dario ;
Napoli, Francesca ;
Rondon-Lagos, Milena ;
Casalone, Elisabetta ;
Lutati, Francesca Vignolo ;
Ogliara, Paola ;
Bironzo, Paolo ;
Gironi, C. Laura ;
Savoia, Paola ;
Maffe, Antonella ;
Ungari, Silvana ;
Grosso, Federica ;
Libener, Roberta ;
Boldorini, Renzo ;
Valiante, Michele ;
Pasini, Barbara ;
Matullo, Giuseppe ;
Scagliotti, Giorgio ;
Magnani, Corrado ;
Dianzani, Irma .
GENES CHROMOSOMES & CANCER, 2018, 57 (11) :573-583
[6]   Genomics and Functional Genomics of Malignant Pleural Mesothelioma [J].
Cakiroglu, Ece ;
Senturk, Serif .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (17) :1-37
[7]   Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM) [J].
Cedres, Susana ;
Ponce-Aix, Santiago ;
Zugazagoitia, Jon ;
Sansano, Irene ;
Enguita, Ana ;
Navarro-Mendivil, Alejandro ;
Martinez-Marti, Alex ;
Martinez, Pablo ;
Felip, Enriqueta .
PLOS ONE, 2015, 10 (03)
[8]   Burden of Mesothelioma Deaths by National Income Category: Current Status and Future Implications [J].
Chimed-Ochir, Odgerel ;
Arachi, Diana ;
Driscoll, Tim ;
Lin, Ro-Ting ;
Takala, Jukka ;
Takahashi, Ken .
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (18) :1-13
[9]   Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial [J].
Disselhorst, Maria J. ;
Quispel-Janssen, Josine ;
Lalezari, Ferry ;
Monkhorst, Kim ;
de Vries, Jeltje F. ;
van der Noort, Vincent ;
Harms, Emmy ;
Burgers, Sjaak ;
Baas, Paul .
LANCET RESPIRATORY MEDICINE, 2019, 7 (03) :260-270
[10]  
Fennell D, 2021, J THORAC ONCOL, V16, pS62
12345